KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Receivables - Net: 2017-2025

Historic Receivables - Net for BeOne Medicines (ONC) over the last 8 years, with Sep 2025 value amounting to $863.3 million.

  • BeOne Medicines' Receivables - Net rose 51.71% to $863.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $863.3 million, marking a year-over-year increase of 51.71%. This contributed to the annual value of $676.3 million for FY2024, which is 88.89% up from last year.
  • As of Q3 2025, BeOne Medicines' Receivables - Net stood at $863.3 million, which was up 12.00% from $770.8 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Receivables - Net registered a high of $863.3 million during Q3 2025, and its lowest value of $73.8 million during Q2 2021.
  • In the last 3 years, BeOne Medicines' Receivables - Net had a median value of $529.4 million in 2024 and averaged $530.7 million.
  • Per our database at Business Quant, BeOne Medicines' Receivables - Net soared by 699.82% in 2021 and then plummeted by 64.16% in 2022.
  • Over the past 5 years, BeOne Medicines' Receivables - Net (Quarterly) stood at $483.1 million in 2021, then tumbled by 64.16% to $173.2 million in 2022, then surged by 106.75% to $358.0 million in 2023, then surged by 88.89% to $676.3 million in 2024, then surged by 51.71% to $863.3 million in 2025.
  • Its last three reported values are $863.3 million in Q3 2025, $770.8 million for Q2 2025, and $717.2 million during Q1 2025.